takeda_usa_pharmaceuticals_u

Takeda’s dengue vaccine proves efficacious in massive Phase 3 trial

pharmafile | January 30, 2019 | News story | Research and Development Dengue fever, TAK-003, Takeda, Vaccine, dengue, health, infectious diseases 

Takeda’s dengue vaccine candidate TAK-003, has proved efficacious in preventing dengue fever in healthy children and adolescents in an ongoing Phase 3 trial.

The tetravalent vaccine, which was found to be well tolerated, met its primary efficacy endpoint in a pivotal Phase 3 trial.

“We are very encouraged by the performance of our dengue vaccine candidate in the study. This brings us one step closer to helping the world tackle the massive burden of dengue,” said Dr Rajeev Venkayya, President of the Global Vaccine Business Unit at Takeda.

“We are excited to publish the data in a peer-reviewed journal as quickly as possible. In parallel, we are advancing the clinical development, commercial manufacturing, and stakeholder consultations to support a potential future global launch of the vaccine.”

The trial enrolled 20,000 healthy children and adolescents between the ages of four and 16, who were living in dengue-endemic areas.

The Japanese firm is also working on vaccines for other highly infectious including Zika, norovirus and polio.   

Louis Goss

Related Content

robina-weermeijer-ihfopazzjhm-unsplash_5

MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment

Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing …

GSK shares new data for RSV vaccine Arexvy

GSK announced positive results from its phase 3 trial which assessed the immune response and …

GSK and Zhifei partner for shingles vaccine promotion in China

GSK has announced that it has come to an exclusive agreement with Chingqing Zhifei Biological …

Latest content